Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$62.27M

FY 2025 · Annual

Investing Cash Flow

-$47.99M

FY 2025 · Annual

Financing Cash Flow

$15,000.00

FY 2025 · Annual

-100.0% YoY

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Net Income(61.89M)(50.33M)(50.31M)(28.92M)(88.61M)
Depreciation & Amortization576.29K596K498K473.86K555K
Deferred Income Tax5.95M688K0675.23K11K
Stock-Based Compensation11.65M12.69M13.05M10.41M8.07M
Change in Working Capital52.43M(19.4M)(11.66M)(26.39M)10.16M
Accounts Receivables37.09M(10.54M)314K(722.38K)5.07M
Inventory00000
Accounts Payables00000
Other Working Capital15.33M(8.85M)(11.98M)(25.67M)5.09M
Other Non-Cash Items468.32K(1.28M)9.07M(10.3M)7.54M
Operating Cash Flow9.19M(57.04M)(39.35M)(54.05M)(62.27M)
Capital Expenditures(1.8M)(545K)(45K)(168.61K)(55K)
Acquisitions (Net)00000
Purchases of Investments0(19.95M)(20.67M)(111.21M)(166.41M)
Sales of Investments13.5M036.18M0118.48M
Other Investing Activities(17.55K)(372K)958K93.82M0
Investing Cash Flow11.71M(20.5M)16.43M(17.55M)(47.99M)
Debt Repayment(284.77K)0(174K)00
Common Stock Issued41.73M52.58M25.33M113.54M15K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow41.45M52.58M25.16M113.54M15K
Effect of Forex Changes(141.71K)(8.12M)(3.02M)47.95K195K
Net Change in Cash62.2M(33.08M)(785K)41.98M(110.05M)
Free Cash Flow7.39M(57.59M)(39.4M)(54.22M)(62.33M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$88.6M
+ D&A$555.0K
+ Stock-Based Comp$8.1M
+ Deferred Tax$11.0K
+ Working Capital$10.2M
+ Other Non-Cash$7.5M
= Operating Cash Flow-$62.3M
- Capex-$55.0K
= Free Cash Flow-$62.3M

Analysis

FY2025 free cash flow is -$62.3M. FCF conversion is 70.3% of net income. Operating cash flow was -$62.3M, with capex of -$55.0K. The largest bridge item is Working Capital at $10.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
DEFA14ADEFA14A filingNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13G/ASC 13G/A filingNov 12, 2026
SC 13GSC 13G filingNov 5, 2026

Does SLN generate free cash flow?

Silence Therapeutics plc (SLN) generated -$62.33M of free cash flow in fiscal 2025.

How much operating cash flow does SLN produce?

Operating cash flow was -$62.27M, before capital expenditures of $55,000.00.